|Bid||35.9200 x 6900|
|Ask||35.9300 x 3300|
|Day's Range||35.8200 - 36.2100|
|52 Week Range||29.8300 - 36.2100|
|PE Ratio (TTM)||26.33|
|Dividend & Yield||1.28 (3.62%)|
|1y Target Est||N/A|
Pfizer said that J&J signed contracts with U.S. health insurers that required patients to "fail first" on Remicade before they considered competitors such as Pfizer's biosimilar, a rival drug that regulators approved as a generic substitute. The contract was required in order for insurers to receive after-market rebates and effectively prevented hospitals and doctors from stocking the biosimilar, Pfizer said.
Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.
Wall Street opened little changed on Wednesday as investors waited for the conclusion of the two-day Federal Reserve meeting for indications of a third interest rate hike this year. Fed Chair Janet Yellen will hold a press conference half an hour later, which will be closely watched for views on inflation.